Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines, Inc. received an ownership report from Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd. Together, the reporting persons state they beneficially own 1,255,162 shares of Praxis common stock, representing 5% of the class as of 12/31/2025.
Orbis Investment Management Ltd reports sole voting and dispositive power over 1,252,573 shares, while Allan Gray Australia Pty Ltd reports sole voting and dispositive power over 2,589 shares. Both firms are non‑U.S. institutions equivalent to investment advisers and certify that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Praxis.
Praxis Precision Medicines, Inc. received an amended Schedule 13G/A from Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross reporting their beneficial ownership in the company’s common stock.
The Reporting Persons collectively hold 965,313 shares of common stock, representing 3.83% of the class, based on 25,195,092 shares outstanding as of December 31, 2025. All shares are held with shared voting and dispositive power and are reported as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Praxis.
Praxis Precision Medicines director Stuart A. Arbuckle reported new equity awards in the company. On February 6, 2026, he received 688 restricted stock units and 478 restricted stock units, each at a price of $0, with vesting tied to 2026 and 2027 service and the 2026 annual meeting. Each unit represents one share of common stock, settled only in shares. He was also granted a stock option for 224 shares at an exercise price of $319.57, vesting in monthly installments from February 26, 2026 until the earlier of June 26, 2026 or the 2026 annual meeting. Following these grants, he beneficially owns 1,166 shares of common stock and 224 stock options, all held directly.
Praxis Precision Medicines director Jeffrey B. Kindler reported new equity awards. On February 6, 2026, he received 688 restricted stock units that vest in two equal annual installments on the first two anniversaries of January 8, 2026.
He was also granted 478 restricted stock units that vest in a single installment on the earlier of June 26, 2026 or the company’s 2026 annual shareholder meeting. Following these grants, he directly holds 1,166 shares of common stock tied to these awards.
In addition, Kindler received a stock option for 224 shares of common stock with a stated exercise price of $319.57 per share, vesting in equal monthly installments from February 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.
Praxis Precision Medicines, Inc. filed an amended current report to update board committee assignments and its Non-Employee Director Compensation Policy, effective February 6, 2026. New directors Jeffrey B. Kindler and Stuart A. Arbuckle, previously elected as Class II directors, received formal committee roles.
Mr. Kindler was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, while Mr. Arbuckle joined the Compensation Committee and the Science and Technology Committee. The amended policy provides Outside Directors a $50,000 annual cash retainer for board service plus additional annual retainers for chair and member roles on key committees, paid quarterly in arrears and prorated for partial service.
The policy also grants equity compensation under the company’s equity plan, including initial restricted stock unit awards and, when applicable, pro rata options and RSUs based on a Black-Scholes valuation and Fair Market Value, along with recurring annual option and RSU awards that vest over one or two years or accelerate upon a Sale Event.
FMR LLC filed a Schedule 13G reporting a passive ownership stake in Praxis Precision Medicines Inc. common stock. FMR LLC and Abigail P. Johnson are reported as beneficial owners of 1,353,275.05 shares, representing 5.4% of the outstanding common stock as of the reporting date.
The securities are certified as acquired and held in the ordinary course of business, not to change or influence control of the company. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the class.
Praxis Precision Medicines, Inc. reported an insider tax-withholding transaction by its Principal Accounting Officer, Lauren Mastrocola. On 01/12/2026, 344 shares of common stock were withheld by the company at a price of $275.74 per share to cover tax obligations arising from the vesting of previously reported restricted stock units. After this automatic withholding, Mastrocola directly beneficially owns 13,445.656 shares of Praxis common stock. The filing is a routine Form 4 disclosure of this non-open-market transaction.
Praxis Precision Medicines Chief Operating Officer Megan Sniecinski reported an automatic withholding of 885 shares of common stock on January 12, 2026. The issuer retained these shares to satisfy tax withholding obligations that arose when previously reported restricted stock units vested, rather than through an open-market sale.
After this tax-related withholding, Sniecinski beneficially owns 28,530 shares of Praxis Precision Medicines common stock, held directly.
Praxis Precision Medicines officer reports tax-related share withholding. General Counsel and Secretary Alex Nemiroff reported that on 01/12/2026, 768 shares of Praxis Precision Medicines common stock were withheld by the company at a price of $275.74 per share. According to the footnote, these shares were withheld by the issuer to cover tax obligations arising from the vesting of previously reported restricted stock units, rather than sold in an open-market transaction. After this withholding, Nemiroff directly beneficially owns 25,932.667 shares of Praxis common stock.
Praxis Precision Medicines, Inc. chief financial officer Kelly Timothy Edwin reported a Form 4 transaction involving company common stock. On January 12, 2026, 943 shares of Praxis common stock were withheld by the issuer at a price of $275.74 per share to cover tax withholding obligations tied to the vesting of previously reported restricted stock units. After this tax-related withholding, Edwin beneficially owned 31,046 shares of Praxis common stock in direct ownership.